Alberto Carturan
YOU?
Author Swipe
View article: SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer
SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer Open
Introduction. Chimeric antigen receptor (CAR) T therapy is now used in second and later lines of treatment in patients with B-cell lymphoma and leukemias, and multiple myeloma. However, patient response rates remain imperfect, with over 60…
View article: Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma
Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma Open
Introduction: Chimeric antigen receptor T-cell (CART) therapy frequently results in profound B- and T-cell depletion. The dynamics and clinical implications of immune reconstitution (IR) post-CART in multiple myeloma (MM) remain understudi…
View article: β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming
β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming Open
Introduction. The impact of patient (pt) lifestyle, particularly diet, on chimeric antigen receptor (CAR) T cell therapy remains poorly understood. In our previous work (ASH 2024, Plenary Session), we identified the ketogenic diet-derived …
View article: Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease Open
Background: Chimeric antigen receptor (CART) therapies targeting CD19 or BCMA have shown great potential for treating autoimmune diseases (AD) in early-phase trials by depleting autoreactive B cells and plasma cells, resetting immune toler…
View article: Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies Open
Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells agai…
View article: CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors—A narrative review
CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors—A narrative review Open
This review addresses the integration of chimeric antigen receptor (CAR)-T cell therapy with reconstructive oncologic surgery in treating peripheral solid tumors, including melanoma, sarcomas, breast cancer, and head and neck cancers. Whil…
View article: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review Open
Cancer immunotherapy—including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)—has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with cancer do…
View article: Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations Open
Numerous cutting-edge immunotherapy approaches have been developed for hematological malignancies, such as immune-checkpoint inhibitors for lymphomas, chimeric antigen receptor (CAR)-T-cell treatments for B-cell cancers, and monoclonal ant…
View article: Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate Open
Introduction. Several mechanisms of resistance have been identified for chimeric antigen receptor (CAR) T cell therapy; however, there are limited data on the impact of lifestyle factors, such as diet, on CAR T cell efficacy. Indeed, diet-…
View article: <i>Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma</i>
<i>Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma</i> Open
Background: Anti-BCMA chimeric antigen receptor T cell (CART-BCMA) immunotherapy is now a standard treatment for relapsed/refractory Multiple Myeloma (MM) after the first line. However, its widespread use might be limited by the need for a…
View article: CD5 deletion enhances the antitumor activity of adoptive T cell therapies
CD5 deletion enhances the antitumor activity of adoptive T cell therapies Open
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several …
View article: Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study Open
Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failur…
View article: A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Open
Introduction: Anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are highly efficacious against advanced B cell non-Hodgkin lymphoma (NHL) but the majority of patients (pts) ultimately fail. Several mechanisms contribute to CART…
View article: Apoptosis: a <i>Janus bifrons</i> in T-cell immunotherapy
Apoptosis: a <i>Janus bifrons</i> in T-cell immunotherapy Open
Immunotherapy has revolutionized the treatment of cancer. In particular, immune checkpoint blockade, bispecific antibodies, and adoptive T-cell transfer have yielded unprecedented clinical results in hematological malignancies and solid ca…
View article: Predictors of Febrile Neutropenia and Role of Levofloxacin Prophylaxis in Acute Myeloid Leukemia And High-Risk Myelodysplastic Syndrome Patients Treated With Hypomethylating Agents
Predictors of Febrile Neutropenia and Role of Levofloxacin Prophylaxis in Acute Myeloid Leukemia And High-Risk Myelodysplastic Syndrome Patients Treated With Hypomethylating Agents Open
Introduction: Prevention of febrile neutropenia in Acute Myeloid Leukemia (AML) and High-Risk Myelodisplastic Syndrome (HR-MDS) patients undergoing treatment with hypomethylating agents (HMAs) remains controversial and there are no clinica…